|
Mar 14
|
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
|
|
Feb 5
|
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
|
|
Dec 18
|
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
|
|
Dec 5
|
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
|
|
Dec 4
|
IntelGenx Announces Changes to its Board of Directors
|
|
Nov 28
|
IntelGenx Announces Shareholder Approval of Financing Transactions
|